What You Should Know:
– Industry veterans Amy Abernethy, M.D., Ph.D., and Brad Hirsch, M.D., have co-founded Highlander Health, a new company dedicated to improving individualized patient care.
– The company is comprised of Highlander Health Institute, a public interest platform, and Highlander Health Partners, an investment arm.
A Vision for Personalized Healthcare
Dr. Abernethy and Dr. Hirsch believe that the healthcare industry needs a more integrated approach to evidence generation and care delivery. Highlander Health aims to bridge this gap by creating flexible solutions that streamline the entire process, from treatment evaluation and approval to widespread adoption.
Highlander Health key focus areas include:
- Evidence Generation: Highlander Health will partner with healthcare systems to conduct rigorous research and generate critical insights.
- Personalized Care: The company will develop solutions that enable more personalized and effective care for patients.
- Technology Enablement: Highlander Health will leverage technology to streamline processes and improve efficiency.
Highlander Health Institute
The Highlander Health Institute will play a crucial role in driving innovation. By partnering with healthcare systems and other industry players, the Institute will create and test new solutions through clinician-led learning labs. The results of these efforts will be shared transparently to advance the field of personalized healthcare.
Highlander Health Partners
As the investment arm of Highlander Health, Highlander Health Partners will provide capital, counsel, and resources to support portfolio companies. The firm’s focus on technology enablement will help drive innovation and growth in the healthcare sector.
“We’re not shying away from big problems,” said Amy Abernethy, co-founder of Highlander Health. “After more than five decades in health care, and seeing the industry’s challenges from all angles, Brad and I are more optimistic than ever. Our experience — across academia, at companies small and large, and at FDA — illuminates the bold solutions needed. And what’s more, how best to assure the commercial viability and utmost impact of any one solution.”
